My watch list
my.bionity.com  
Login  

5 Current news of Takara Bio

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Takara Bio Europe Goes Direct in 2012

Clontech owner demonstrates confidence in European research market by establishing wholly-owned sales organisation

02-Feb-2012

Takara Bio Europe announced that it will start selling its range of Takara brand products exclusively and directly to customers in the UK, Germany, Austria and Switzerland, with immediate effect. The decision means customers will be able to buy both Takara and Clontech brand products from one ...

more

MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market

30-Nov-2010

MDxHealth SA announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc.. Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation ...

more

Clontech Laboratories & TET Systems Announce the Broadening of Their License Agreement

28-Jul-2010

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems, a privately-held German biotech company based in Heidelberg, announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights ...

more

Takara Bio to Acquire Clontech Unit of BD Biosciences

05-Jul-2005

Takara Bio Inc. announced that it has entered into a definitive agreement to acquire the Clontech unit ("Clontech") of BD Biosciences, mainly consisting of Clontech Laboratories Inc. (employees: 190), for USD $60 million (adjusted from USD $65 million due to the retention of certain inventories ...

more

Takara Bio: Clinical Development of "Cancer Immunotherapy" jointly performed with CI&H, Chinese Academy of Medical Sciences

17-Sep-2004

Takara Bio Inc. agreed on August 31, 2004 to undertake clinical development of cancer immunotherapy intended for commercialization jointly with Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing. Presently, in China, too, malignant tumor is the leading cause of death, ...

more

Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE